Study Links GLP-1 Use in Diabetes and Obesity to Higher Bone-Related Condition Rates
Similar Articles
Study Finds Weight Loss via GLP-1 Medications Attracts More Stigma Than Diet and Exercise
GLP-1 Medications Linked to Reduced Psychiatric Hospitalizations and Sick Leave
Endoscopic Procedure Shows Promise in Preventing Weight Regain After GLP-1 Medication Use
Semaglutide Shows Significant Weight Loss Benefits for Older Adults with Obesity
New Enzyme Discovery Could Improve GLP-1 Drugs Like Ozempic and Wegovy
A new observational study presented at the 2026 American Academy of Orthopaedic Surgeons (AAOS) annual meeting has found an association between GLP-1 medication use and higher rates of osteoporosis, osteomalacia, and gout among adults with type 2 diabetes and obesity. The study, which has not yet been peer reviewed, analyzed data from nearly 147,000 patients. Researchers noted that rapid weight loss can reduce bone density, and the study did not account for several lifestyle and health factors.
Facts First
- GLP-1 use was associated with higher rates of osteoporosis, osteomalacia, and gout in a study of nearly 147,000 adults with type 2 diabetes and obesity.
- The findings are preliminary, as the study was observational and has not yet been peer reviewed.
- The analysis had limitations, including not accounting for exercise, nutrition, or family history, and assuming prescription records equated to medication use.
- Rapid weight loss can reduce bone density, as bone formation decreases when weight drops quickly.
- Directories for finding board-certified obesity medicine physicians are maintained by the American Board of Obesity Medicine and the Obesity Action Coalition.
What Happened
A study presented at the 2026 American Academy of Orthopaedic Surgeons (AAOS) annual meeting found that among nearly 147,000 adults with type 2 diabetes and obesity, GLP-1 use was associated with higher rates of osteoporosis, osteomalacia, and gout. The study was observational and has not yet been peer reviewed. It did not account for factors such as exercise habits, nutrition, endocrine conditions, alcohol use, or family history. The research also assumed that everyone listed as being prescribed a GLP-1 in their medical records was actually taking it.
Why this Matters to You
If you are taking a GLP-1 medication for weight loss or diabetes, this preliminary finding suggests you may want to discuss bone health with your doctor. Rapid weight loss, which these medications can facilitate, is known to reduce bone density over time because bone formation decreases when weight drops quickly. A general target for gradual weight loss is losing five to ten percent of total body weight over roughly six months, or approximately 0.5 to 2 pounds per week. Ensuring adequate protein intake—the standard recommendation is 0.8 grams per kilogram of body weight per day—could be one factor to consider, though the study did not evaluate nutrition's role.
What's Next
The study's findings require peer review and further research to confirm the association and understand the underlying causes. Patients concerned about these potential risks may want to consult a specialist; the American Board of Obesity Medicine and the Obesity Action Coalition maintain directories for finding board-certified obesity medicine physicians. Future studies will likely need to account for the lifestyle and health factors this initial analysis did not.